1. Kingwell, E, Marriott, JJ, Jette, N, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 2013; 13: 128.
Google Scholar | Crossref | Medline | ISI2. Baird, SM, Dalton, J. Multiple sclerosis in pregnancy. J Perinat Neonatal Nurs 2013; 27: 232–241.
Google Scholar | Crossref | Medline3. Confavreux, C, Hutchinson, M, Hours, MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339: 285–291.
Google Scholar4. Vukusic, S, Hutchinson, M, Hours, M, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004; 127: 1353–1360.
Google Scholar5. Langer-Gould, A, Smith, JB, Albers, KB, et al. Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. Neurology 2020; 94: e1939–e1949.
Google Scholar6. Cuello, JP, Martinez Gines, ML, Kuhle, J, et al. Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study. Eur J Neurol 2019; 26: 1200–1204.
Google Scholar | Crossref | Medline7. Amato, MP, Portaccio, E. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs 2015; 29: 207–220.
Google Scholar | Crossref | Medline8. Lopez-Leon, S, Geissbuhler, Y, Sabido, M, et al. A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project. J Neurol 2020; 267: 2721–2731.
Google Scholar | Crossref | Medline9. Rebif . Rebif (interferon beta-1a) European summary of product characteristics, https://www.ema.europa.eu/en/medicines/human/EPAR/rebif (2019, accessed 23 April 2020).
Google Scholar10. Avonex . AVONEX (interferon beta-1a) European summary of product characteristics, 2019, https://www.ema.europa.eu/en/medicines/human/EPAR/avonex
Google Scholar11. Betaferon . Betaferon (interferon beta-1b) European summary of product characteristics, 2019, https://www.ema.europa.eu/en/medicines/human/EPAR/betaferon
Google Scholar12. Extavia . Extavia (interferon beta-1b) European summary of product characteristics, 2020, https://www.ema.europa.eu/en/medicines/human/EPAR/extavia
Google Scholar13. Copaxone . Copaxone (glatiramer acetate injection) summary of product characteristics, 2019, https://www.medicines.org.uk/emc/product/7046/smpc#gref
Google Scholar14. Sorensen, PS, Koch-Henriksen, N, Petersen, T, et al. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol 2014; 261: 1170–1177.
Google Scholar15. Krysko, KM, Rutatangwa, A, Graves, J, et al. Association between breastfeeding and postpartum multiple sclerosis relapses: a systematic review and meta-analysis. JAMA Neurol 2020; 77: 327–338.
Google Scholar | Crossref | Medline16. Higgins, JPT, Green, S. Cochrane handbook for systematic reviews of interventions, v5.1.0. London: The Cochrane Collaboration, 2011.
Google Scholar17. Wells, G, O’Connell, D, Peterson, J, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (2014, accessed 20 May 2016).
Google Scholar18. Alroughani, R, Ahmed, S, Elsherbeny, D, et al. The use natalizumab in multiple sclerosis is safe and prevents disease reactivation. Neurology 2019; 92: P4.2093.
Google Scholar19. Alroughani, R, Akhtar, S, Zeineddine, M, et al. Risk of relapses during pregnancy among multiple sclerosis patients. Mult Scler Relat Disord 2019; 34: 9–13.
Google Scholar | Crossref | Medline20. Amato, M, Portaccio, E, Tortorella, C, et al. Disease re-activation during pregnancy after natalizumab suspension in patients with multiple sclerosis. J Neurol Sci 2015; 357: e297.
Google Scholar | Crossref | Medline21. Berenguer-Ruiz, L, Gimenez-Martinez, J, Palazon-Bru, A, et al. Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy. J Neurol 2019; 266: 2512–2517.
Google Scholar | Crossref | Medline22. Bsteh, G, Algrang, L, Hegen, H, et al. Pregnancy and multiple sclerosis in the DMT era: a cohort study in Western Austria. Mult Scler 2020; 26: 69–78.
Google Scholar | SAGE Journals | ISI23. Cuello, JP, Salgado Camara, P, Garcia Dominguez, JM, et al. Pregnancy exposure to disease-modifying drugs in multiple sclerosis: a prospective study. Med Clin 2020; 154: 214–217.
Google Scholar | Crossref | Medline24. Esters, N, Spicher, C, Thiel, S, et al. Disease activity and disability after natalizumab (NTZ) withdrawal due to planning a pregnancy in women with multiple sclerosis. Neurology 2018; 90: P4.358.
Google Scholar25. Fragoso, YD, Boggild, M, Macias-Islas, MA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin Neurol Neurosurg 2013; 115: 154–159.
Google Scholar | Crossref | Medline | ISI26. Hellwig, K, Haghikia, A, Rockhoff, M, et al. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord 2012; 5: 247–253.
Google Scholar | SAGE Journals | ISI27. Hellwig, K, Haghikia, A, Gold, R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler 2011; 17: 958–963.
Google Scholar | SAGE Journals | ISI28. Hemat, S, Thiel, S, Gold, R, et al. Disease activity during pregnancy after fingolimod withdrawal due to planning a pregnancy in women with multiple sclerosis. Mult Scler 2018; 24: 74–75.
Google Scholar29. Herbstritt, S, Gold, R, Hellwig, K. ‘Injectables’ during pregnancy in women with multiple sclerosis. Mult Scler 2015; 23: 112–113.
Google Scholar30. Kleerekooper, I, van Kempen, ZLE, Leurs, CE, et al. Disease activity following pregnancy-related discontinuation of natalizumab in MS. Neurol Neuroimmunol Neuroinflamm 2018; 5: e424.
Google Scholar | Crossref | Medline31. Pardo, K, Katorza, E, Ziv-Baran, T, et al. Does use of disease modified therapies for multiple sclerosis affect fertility and pregnancy outcomes? Mult Scler 2018; 24: 509–510.
Google Scholar32. Portaccio, E, Moiola, L, Martinelli, V, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: maternal risks. Neurology 2018; 90: e832–e839.
Google Scholar | Crossref | Medline33. Thiel, S, Langer-Gould, A, Rockhoff, M, et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler 2016; 22: 801–809.
Google Scholar | SAGE Journals | ISI34. Hemat, S, Hellwig, K, Houtchens, M, et al. Disease activity during pregnancy after fingolimod withdrawal due to planning a pregnancy in women with multiple sclerosis. Neurology 2018; 90: P5.032.
Google Scholar35. Alroughani, R, Alowayesh, MS, Ahmed, SF, et al. Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. Neurology 2018; 90: e840–e846.
Google Scholar | Crossref | Medline36. Beaber, BE, Chi, MD, Brara, SM, et al. Immunomodulatory agents and risk of postpartum multiple sclerosis relapses. Perm J 2014; 18: 9–13.
Google Scholar | Crossref | Medline37. Hellwig, K, Rockhoff, M, Herbstritt, S, et al. Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses. JAMA Neurol 2015; 72: 1132–1138.
Google Scholar | Crossref | Medline | ISI38. Hughes, SE, Spelman, T, Gray, OM, et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler 2014; 20: 739–746.
Google Scholar | SAGE Journals | ISI39. Jesus-Ribeiro, J, Correia, I, Martins, AI, et al. Pregnancy in multiple sclerosis: a Portuguese cohort study. Mult Scler Relat Disord 2017; 17: 63–68.
Google Scholar | Crossref | Medline40. Manieri, MC, Mahlanza, TD, Houtchens, M. Disease-modifying therapies, fertility and post-partum multiple sclerosis course: interim data from PREG-MS cohort. Mult Scler 2018; 24: 352.
Google Scholar41. Popova, E, Boyko, A. Retrospective analysis of the effect of pregnancy on the course of multiple sclerosis in Russia. J Neurol Sci 2015; 357: e300.
Google Scholar | Crossref | Medline42. Portaccio, E, Ghezzi, A, Hakiki, B, et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology 2011; 77: 145–150.
Google Scholar | Crossref | Medline | ISI43. Portaccio, E, Ghezzi, A, Hakiki, B, et al. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. J Neurol Neurosurg Psychiatry 2014; 85: 845–850.
Google Scholar | Crossref | Medline44. Vukusic, S, Durand-Dubief, F, Benoit, A, et al. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. Mult Scler 2015; 21: 953–955.
Google Scholar | SAGE Journals | ISI45. Sahebi Vaighan, N, Ghozat, R, Abadi, A, et al. The effect of exclusive breastfeeding on postpartum multiple sclerosis relapses. Mult Scler 2017; 2017: 705–706.
Google Scholar46. Kerbrat, A, Le Page, E, Leray, E, et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci 2011; 308: 98–102.
Google Scholar | Crossref | Medline | ISI47. Vukusic, S, Marignier, R. Multiple sclerosis and pregnancy in the ‘treatment era’. Nat Rev Neurol 2015; 11: 280–289.
Google Scholar | Crossref | Medline48. Howie, PW, McNeilly, AS. Breast-feeding and postpartum ovulation. IPPF Med Bull 1982; 16: 1–3.
Google Scholar | Medline49. Datta, P, Ciplea, AI, Rewers-Felkins, K, et al. Cladribine transfer into human milk: a case report. Mult Scler J 2021; 27: 799–801.
Google Scholar | SAGE Journals | ISI50. Proschmann, U, Thomas, K, Thiel, S, et al. Natalizumab during pregnancy and lactation. Mult Scler J 2017; 24: 1627–1634.
Google Scholar | SAGE Journals51. Interferon beta . In: Drugs and Lactation Database (LactMed). Bethesda, MD: National Library of Medicine (US), 2006, https://www.ncbi.nlm.nih.gov/books/NBK501168/
Google Scholar52. Ciplea, AI, Datta, P, Rewers-Felkins, K, et al. Dimethyl fumarate transfer into human milk. Ther Adv Neurol Disord 2020; 13: 1756286420968414.
Google Scholar | SAGE Journals